Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Inventory (2021 - 2025)

Indivior Pharmaceuticals has reported Inventory over the past 5 years, most recently at $153.0 million for Q4 2025.

  • Quarterly results put Inventory at $153.0 million for Q4 2025, down 8.38% from a year ago — trailing twelve months through Dec 2025 was $153.0 million (down 8.38% YoY), and the annual figure for FY2025 was $153.0 million, down 8.38%.
  • Inventory for Q4 2025 was $153.0 million at Indivior Pharmaceuticals, down from $155.0 million in the prior quarter.
  • Over the last five years, Inventory for INDV hit a ceiling of $167.0 million in Q4 2024 and a floor of $95.0 million in Q4 2021.
  • Median Inventory over the past 5 years was $151.0 million (2025), compared with a mean of $140.2 million.
  • Biggest five-year swings in Inventory: skyrocketed 32.54% in 2024 and later decreased 8.38% in 2025.
  • Indivior Pharmaceuticals' Inventory stood at $95.0 million in 2021, then increased by 20.0% to $114.0 million in 2022, then grew by 10.53% to $126.0 million in 2023, then skyrocketed by 32.54% to $167.0 million in 2024, then decreased by 8.38% to $153.0 million in 2025.
  • The last three reported values for Inventory were $153.0 million (Q4 2025), $155.0 million (Q3 2025), and $149.0 million (Q2 2025) per Business Quant data.